论文部分内容阅读
目的评价地特胰岛素(Det)联合瑞格列奈对老年T2DM患者的疗效及安全性。方法 60例老年T2DM患者分为Det联合瑞格列奈(A)组和预混胰岛素(B)组进行治疗,观察治疗前后FBG、2hBG、HbA1c、BMI、血糖波动幅度(MAGE)、低血糖的频率及程度等情况。结果治疗后,两组FBG、2hBG、HbA1c下降(P<0.05),A组低血糖发生率、程度及MAGE均低于B组(P<0.05);A组体重下降0.49kg,B组体重增加1.48kg,差异无统计学意义(P>0.05)。结论地特胰岛素联合瑞格列奈可降低老年T2DM患者血糖,且低血糖发生率低,安全性高。
Objective To evaluate the efficacy and safety of detemir (Det) combined with repaglinide in elderly patients with T2DM. Methods Sixty elderly T2DM patients were divided into Det combined with repaglinide (Group A) and premixed insulin (Group B) for treatment. The levels of FBG, 2hBG, HbA1c, BMI, MAGE and Hypoglycemia before and after treatment were observed. Frequency and degree of situation. Results After treatment, the FBG, 2hBG and HbA1c in both groups decreased (P <0.05). The incidence of hypoglycemia, MAGE in group A were lower than those in group B (P <0.05) 1.48kg, the difference was not statistically significant (P> 0.05). Conclusion Detemir insulin combined with repaglinide can reduce blood glucose in elderly patients with T2DM, and low incidence of hypoglycemia, high safety.